Nuvation Bio (NUVB) Non Operating Investment Income (2023 - 2026)
Nuvation Bio (NUVB) posted quarterly Non Operating Investment Income of $8000.0 for Q1 2026, up 166.67% year-over-year from $3000.0 in Q1 2025, and up 166.67% quarter-over-quarter from $3000.0 in Q4 2025.
Powered by 
Analysis
Nuvation Bio (NUVB) Non Operating Investment Income (2023 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Non Operating Investment Income for 4 consecutive years, with $8000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 166.67% year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $10000.0 (up 200.0% YoY), while the FY2025 annual figure was $5000.0, up 141.67% from the prior year.
- Non Operating Investment Income grew to $8000.0 in Q1 2026 per NUVB's latest filing, from $3000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $44000.0 in Q4 2023 and bottomed at -$99000.0 in Q2 2023.
- Historically, Non Operating Investment Income has averaged -$3818.2 across 4 years, with a median of $3000.0 in 2025.
- Annual changes were most pronounced in 2024 — Non Operating Investment Income tumbled 191.67% — and 2025, when it jumped 200.0%.
- Nuvation Bio's Non Operating Investment Income stood at $44000.0 in 2023, then slumped by 88.64% to $5000.0 in 2024, then sank by 40.0% to $3000.0 in 2025, then surged by 166.67% to $8000.0 in 2026.
- Business Quant data shows NUVB's Non Operating Investment Income at $8000.0 in Q1 2026, $3000.0 in Q4 2025, and -$1000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Nuvation Bio | 2.38 Bn | 2.38 Bn | 30.78 Mn | 9,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -7,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Dec 31, 2023 | 44,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | -99,000.00 |